SOPHiA GENETICS’s (SOPH) Buy Rating Reaffirmed at HC Wainwright

SOPHiA GENETICS (NASDAQ:SOPH)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a research note issued to investors on Monday, Benzinga reports. They currently have a $14.00 price objective on the stock. HC Wainwright’s price target would indicate a potential upside of 97.60% from the stock’s previous close.

Several other research analysts also recently commented on SOPH. BTIG Research boosted their target price on SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Friday, July 17th. Finally, Zacks Research raised shares of SOPHiA GENETICS to a “hold” rating in a report on Tuesday, July 21st. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $10.00.

SOPHiA GENETICS Price Performance

Shares of NASDAQ:SOPH traded down $0.01 during trading on Monday, reaching $7.09. 69,516 shares of the company traded hands, compared to its average volume of 308,651. The firm has a market capitalization of $594.36 million, a PE ratio of -6.18 and a beta of 0.95. SOPHiA GENETICS has a 52 week low of $3.75 and a 52 week high of $8.98. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 0.58. The company’s 50 day moving average is $7.95 and its two-hundred day moving average is $6.20.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). SOPHiA GENETICS had a negative return on equity of 132.47% and a negative net margin of 93.86%. The company had revenue of $23.31 million during the quarter, compared to the consensus estimate of $21.72 million. As a group, sell-side analysts predict that SOPHiA GENETICS will post -0.77 earnings per share for the current year.

Insider Buying and Selling

In other SOPHiA GENETICS news, CEO Ross Muken sold 9,838 shares of the stock in a transaction that occurred on Monday, October 5th. The stock was sold at an average price of $8.13, for a total value of $79,982.94. Following the transaction, the chief executive officer owned 660,391 shares in the company, valued at approximately $5,368,978.83. This represents a 1.47% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Chairman Jurgi Camblong sold 40,172 shares of SOPHiA GENETICS stock in a transaction on Monday, October 5th. The shares were sold at an average price of $8.13, for a total transaction of $326,598.36. Following the completion of the sale, the chairman directly owned 3,395,650 shares of the company’s stock, valued at approximately $27,606,634.50. The trade was a 1.17% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 282,543 shares of company stock valued at $2,130,026 over the last quarter. Insiders own 4.88% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the company. AWM Investment Company Inc. bought a new stake in shares of SOPHiA GENETICS in the 2nd quarter worth approximately $9,809,000. Principal Financial Group Inc. boosted its position in shares of SOPHiA GENETICS by 0.7% in the first quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company’s stock valued at $6,976,000 after acquiring an additional 9,800 shares during the period. Hodges Capital Management Inc. bought a new position in SOPHiA GENETICS in the 1st quarter valued at $2,157,000. Sei Investments Co. bought a new position in SOPHiA GENETICS in the 1st quarter worth about $1,772,000. Finally, 1492 Capital Management LLC raised its stake in SOPHiA GENETICS by 8.4% in the first quarter. 1492 Capital Management LLC now owns 225,751 shares of the company’s stock valued at $1,117,000 after purchasing an additional 17,406 shares in the last quarter. 31.59% of the stock is owned by institutional investors.

About SOPHiA GENETICS

SOPHiA GENETICS is a healthcare technology company that develops cloud-based data analytics solutions for the life sciences and healthcare industries. Its platform is designed to help organizations analyze and interpret complex genomic and multimodal data to support more informed clinical and research decisions.

The company’s principal offering, the SOPHiA DDM platform, combines data management, analytics and artificial intelligence capabilities. It supports applications including cancer genomics, hereditary disease analysis, reproductive health and other areas of precision medicine.